At the Pharma Partnering US Summit 2026, the nation’s elite business development, licensing (BD&L), and investment executives converged to architect the next generation of biopharma alliances.
Intelligencia AI stepped directly into the spotlight at this high-stakes forum, actively participating in a dynamic panel discussion centered on accelerating due diligence and asset optimization. On stage and on the floor, our team demonstrated how purpose-built machine learning ecosystems completely eliminate historical blind spots from asset valuation. By delivering objective, data-driven transparency on a drug’s true probability of technical and regulatory success (PTRS), our predictive analytics platform empowers cross-functional teams to eliminate guesswork from transactions, mitigate structural pipeline risks, and confidently secure high-value clinical partnerships.
